Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amphastar Pharmaceuticals Inc (AMPH) vs Diageo plc (DEO) Price & Performance

Amphastar Pharmaceuticals IncTrade
Diageo plcTrade

Price performance (Past 24H)

Key statistics

Amphastar Pharmaceuticals Inc vs Diageo plc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Diageo plc trades at $94.15 (market cap $53.75B). The key difference: Diageo plc is far larger — about 62.2× Amphastar Pharmaceuticals Inc's market cap, and Diageo plc pays a 3.42% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

AMPHDEO
Market Cap
$863.95M$53.75B
Sector
HealthTechnology
52-Week High
$30.81$115.33
52-Week Low
$16.87$72.47
Enterprise Value
$1.26B$73.25B
Dividend Yield
3.42%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amphastar Pharmaceuticals Inc

AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.

Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.

Diageo plc

Diageo (DEO) trades at $96.35, up 3.83% with bullish technical signals from moving averages. The company reported mixed FY2026 results with a 2% organic sales decline but 2% operating profit growth, supported by cost savings. Analyst consensus leans positive with 48.65% buy ratings, though valuation metrics appear elevated with a P/E of 31.16. Recent news highlights a $1 billion cost-cutting plan and strategic focus on spirits and Guinness to drive turnaround.

The outlook is cautiously optimistic with management's restructuring program expected to improve margins and cash flow. Key risks include ongoing weakness in North American markets and competitive pressures. Wall Street sees potential upside with recent target increases, but investors should monitor execution of the turnaround plan amid challenging market conditions.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amphastar Pharmaceuticals Inc

Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.

Read more on AMPH

About Diageo plc

Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Smirnoff, and Guinness. It operates a vast portfolio of spirits and beers across more than 180 countries.

Read more on DEO